

CÔNG TY CỔ PHẦN
DƯỢC LIỆU VIỆT NAM
VIET NAM MEDICINAL MATERIALS
JOINT STOCK COMPANY

Số: 10/2025/ DLVN-CBTT

CỘNG HOÀ XÃ HỘI CHỦ NGHĨA VIỆT NAM
Độc lập - Tự do - Hạnh phúc

THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom –Happiness

Hà Nội, ngày 17 tháng 06 năm 2025
June 17th 2025

**CÔNG BỐ THÔNG TIN ĐỊNH KỲ
PERIODIC DISCLOSURE**

Kính gửi: - Sở Giao dịch Chứng khoán Hà Nội

Respectfully to - Hanoi Stock Exchange

- Tên tổ chức/Organization name: Công ty Cổ phần Dược liệu Việt Nam/ Viet Nam Medicinal Materials Joint Stock Company
 - Mã chứng khoán/ Stock code: **DVM**
 - Địa chỉ/Address: Khu 8, xã Phù Ninh, huyện Phù Ninh, tỉnh Phú Thọ, Việt Nam
 - Điện thoại liên hệ/ Tel: 0243.984.1255
 - Người thực hiện công bố thông tin/ The person responsible for information disclosure: Bà Nguyễn Thị Tuyết Mai - Người được ủy quyền CBTT/ Mrs. Nguyen Thi Tuyen Mai - The authorized person for information disclosure
 - Loại thông tin công bố: ☒ Định kỳ/Periodic
- Nội dung thông tin công bố: Ngày 17/06/2025, Công ty CP Dược Liệu Việt Nam trân trọng công bố Biên bản họp và Nghị quyết Đại hội đồng cổ đông thường niên năm tài chính 2025 / Viet Nam Medicinal Materials Joint Stock Company respectfully announce the Meeting Minutes and Resolution of the Annual General Meeting of Shareholders for the fiscal year 2024
- Thông tin này đã được công bố trên trang thông tin điện tử của công ty vào ngày 17/06/2025 tại đường dẫn: <https://duoclieuvietnam.com.vn/>. /This information was published on the Company's website on June 17 2025 as in the link: <https://duoclieuvietnam.com.vn/>.

Chúng tôi xin cam kết các thông tin công bố trên đây là đúng sự thật và hoàn toàn chịu trách nhiệm trước pháp luật về nội dung các thông tin đã công bố./ *We hereby certify that the information provided is true and accurate and we bear the full responsibility to the law for the content of the disclosed information.*



Nơi nhận:


- Như trên;
- CBTT: (IDS,CIMS,Web);
- Lưu VP;

Recipients:

- As above
- Archives VP;

Đại diện tổ chức

Người được ủy quyền công bố thông tin
The authorized person for information disclosure



NGUYỄN THỊ TUYẾT MAI



**REPORT OF THE BOARD OF DIRECTORS AT THE 2025
ANNUAL GENERAL MEETING OF SHAREHOLDERS**

**To: Esteemed Shareholders of Viet Nam Medicinal Materials Joint Stock
Company (DVM)**

*Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020
issued by the National Assembly of the Socialist Republic of Vietnam;*

*Pursuant to the Law on Securities No. 54/2019/QH14 dated November 26, 2019
issued by the National Assembly of the Socialist Republic of Vietnam;*

Pursuant to the Charter of Viet Nam Medicinal Materials Joint Stock Company;

Pursuant to the Operating Regulations of the Board of Directors.

On behalf of the Board of Directors (BOD) of Viet Nam Medicinal Materials Joint Stock Company, we respectfully present to the Annual General Meeting of Shareholders (AGM) the 2024 business performance results, activities of the Board of Directors in 2024, and the 2025 business plan as follows:

PART I

BUSINESS PERFORMANCE REPORT FOR 2024

I. Business Results in 2024

2024 marked a year of continued stability in the pharmaceutical industry, which is still considered to have significant potential despite facing certain challenges.

The hospital channel (ETC), which accounts for a major portion of industry

revenue, was expected to maintain its growth thanks to the national health insurance policy and the relaxation and improvement of hospital drug bidding regulations. Additionally, demand for specialized pharmaceutical products continued to rise, especially for orphan drugs, biologics, and medicines for severe diseases. Meanwhile, although the pharmacy channel (OTC) did not experience a remarkable increase in revenue, it was widely expected to see more positive developments in 2025.

Overall, as an essential sector with low sensitivity to market fluctuations and economic downturns, the pharmaceutical industry in 2024 saw growth in both imports and domestic production. Under the direction of the Board of Directors, the determined and close guidance of the Executive Board, and the concerted efforts of all staff members, the Company achieved the following results in 2024:

Indicator	Unit	Actual 2024	Compared to 2023		Compared to 2024 Plan	
			Actual 2023	% increase/ decrease	2024 Plan	% of Plan Achieved
Net revenue	VND Billion	1,579.97	1,481.72	6.63%	1,200	131.66%
Total profit before tax	VND Billion	55.40	49.50	11.91%	59.7	92.80%
Total profit after tax	VND Billion	47.88	43.16	10.92%	49.55	96.73%
Basic earnings per share	VND	1,119	1,211	-	1,158	96.63%

In 2024, the Company exceeded its revenue target by 131.66% and achieved 96.73% of the profit target. The main reason was the restructuring of the sales mechanism, which led to a significant reduction in total selling expenses—from VND 25.67 billion in 2023 to VND 11.25 billion in 2024—equivalent to a 56.17% decrease. In addition, effective loan management contributed to a 20.6% reduction in financial expenses compared to 2023.

II. Departmental Performance in 2024

❖ *Product Research and Development Activities*

Research, development, and product registration have remained top priorities for the Company with the goal of continuously improving capabilities and providing the market with the highest quality products.

In 2024, the Company successfully conducted research and registered dossiers for health supplement products and traditional medicine products under contract manufacturing agreements with partner units. The Company developed over 900 products, including dry extracts, herbal granules, herbal medicines, traditional medicines, Oriental medicine ingredients, and nutritional products (such as milk powders). At the Phu Tho Department of Health, the Company self-declared and registered 337 products. At the Vietnam Food Administration (VFA), the Administration of Traditional Medicine (Cục YDCT), and the Drug Administration of Vietnam (DAV), 563 products were submitted for registration, of which 265 have been approved; the remaining products are undergoing the completion of registration procedures.

In addition to product research, in 2024 the Company's R&D Department also collaborated with external partners to carry out several scientific projects, as detailed below:

No.	Project Title	Partner Organization
1	Observational, open-label, controlled study evaluating the efficacy and safety of traditional herbal granules in the treatment of patients using prescribed Oriental medicine formulas	Institute of Traditional Medicine
2	PROJECT: PRODUCTION OF CAPSULES CONTAINING COLLAGEN EXTRACTED FROM FISH SCALES AND OMEGA-3,6,9-RICH OIL FROM SACHI SEEDS (Plukenetia volubilis)	Institute of Tropical Technology (Vietnam Academy of Science and Technology)

❖ ***Manufacturing Operations at the Plant***

- Quality control and evaluation are implemented continuously and rigorously:
 - + 100% of raw materials are sampled and inspected upon arrival; only those meeting quality standards are approved for warehousing and production;
 - + 100% of finished products are inspected for quality against registered

standards; only products that meet quality requirements are released.

- In 2024, the Company's WHO-GMP certified manufacturing plant processed approximately 2,000 tons of medicinal herbs, extracted 16.8 tons of herbal concentrate, produced 6.5 million packets of herbal granules/traditional medicine, 100,000 liters of liquid medicines, and 2.8 million units of solid dosage forms. These figures demonstrate the production capacity of Viet Nam Medicinal Materials Joint Stock Company (VIETMEC), which is capable of meeting high annual demand and can further scale as needed by customers.
- Labor arrangements at the manufacturing plant were appropriately managed; production workshops arranged overtime shifts depending on actual production demands at each time to meet business needs. The plant also ensured workers attended full training sessions on GMP, standard operating procedures (SOPs), occupational safety and hygiene, and fire and explosion prevention. Special attention was paid to equipment operation training for production line workers to ensure sufficient human resources are available in case of staff turnover.

❖ *Distribution and Sales Activities*

The Company's sales network spans across all provinces and cities nationwide within the traditional medicine and pharmaceutical sector. Sales operations across business divisions were actively promoted, enhancing brand recognition. Business and marketing departments closely collaborated to develop flexible, practical sales programs. Monitoring, tracking, and reporting systems were standardized through specialized software to improve operational efficiency and managerial effectiveness.

In 2024, total sales revenue reached VND 1,580.02 billion, of which: Western medicine, traditional medicine, and health supplements contributed VND 877.48 billion (55%), Medical supplies contributed VND 65.4 billion (2.1%), Herbal medicine products contributed VND 580.2 billion (36.8%), Other sources accounted for a minor portion.

In 2024, the Company implemented its sales through various distribution channels, including:

- A chain of GPP-certified pharmacies (certified by provincial Departments of Health), mainly focused on selling western medicines, oriental medicines, consumable medical supplies, cosmetics, and the Company's health supplements.
- The Tender Sales Division developed sales channels into hospitals, medical centers, public and private healthcare facilities, and certain businesses.

- The OTC Sales Division conducted nationwide distribution through a network of medical representatives and sales partners. This was also the year in which the Company continued to strengthen its collaboration with distribution companies.

With a rational recruitment and compensation policy, the Company is gradually building a team of professional, dynamic, creative, and enthusiastic sales staff. Commercial sales are being promoted as one of the promising and efficient business segments in the near future.

❖ **Financial Activities**

Financial activities at Viet Nam Medicinal Materials Joint Stock Company were carried out accurately and comprehensively, truthfully reflecting the Company's financial status and business performance. Compliance with accounting regulations, standards, and related legal provisions was ensured. The Company views legal compliance not only as a regulatory requirement but also as a core responsibility of an ethical business entity.

Detailed financial figures are presented in the 2024 Audited Financial Statements and the 2024 Annual Report.

In 2024, the Company's total assets increased by 6.7% compared to the previous year, mainly due to growth in long-term receivables, long-term work-in-progress assets, and investments in associates. Long-term receivables stemmed from investment cooperation in developing cultivation zones for rare medicinal herbs in Lao Cai, Tuyen Quang, and Ninh Thuan provinces. Additionally, the Company acquired land to expand its branches in Hai Phong and Da Nang, and invested in associated companies to broaden its market reach and enhance product distribution networks.

In 2024, net revenue increased by 7% year-on-year, reaching VND 1,579.97 billion. Net profit from business activities after tax also grew by 11% compared to 2023, amounting to nearly VND 48 billion. This growth was attributed to cost reduction initiatives, negotiations with suppliers for better input prices, and other efficiency improvements.

However, due to the broader economic downturn and industry-wide pressures, profitability ratios such as return on sales (ROS), return on equity (ROE), and return on assets (ROA) remained relatively low—at 3%, 6.5%, and 2.9%, respectively—largely due to the high costs associated with in-house herbal medicine production. DVM has developed medium- and long-term strategies to secure raw herbal material

sources to minimize input price volatility. In addition, as the economy is expected to enter a new growth cycle, DVM anticipates improved profitability and sustainable growth in the years ahead.

III. Human Resource Policy

Employee Classification by Educational Level		Number of Employees	Proportion (%)
<i>Postgraduate</i>	<i>Total</i>	2	1%
	Master's Degree	2	1%
<i>University Degree</i>	<i>Total</i>	118	50%
	Pharmacy	17	7%
	Others	101	43%
<i>College / Intermediate Level</i>	<i>Total</i>	96	41%
	College of Pharmacy	52	22%
	Other Colleges	11	5%
	Intermediate Pharmacy	12	5%
	Other Intermediate Levels	10	4%
	Others	11	5%
<i>Others (collaborations)</i>		19	8%
TOTAL		234	234

Human resources are always considered the core of sustainable development. As of December 31, 2024, VIETMEC had a total of 234 personnel, including 208 employees under official labor contracts and 26 under probation or collaborator contracts. Of these, 175 employees were participating in the Company's social insurance program, accounting for 75% (excluding collaborators, individuals insured through other entities, and those receiving retirement pensions). The number of employees with educational qualifications from intermediate level and above was 223 (95%), while the total number of pharmacists (intermediate/college/university level) was 81, accounting for 34.6%.

Average Total Income per Employee: 2023: VND 9,500,000, 2024: VND 11,900,000 (an increase of 25% compared to the previous year); This demonstrates the Company's continuous commitment to improving employees' quality of life and ensuring their lawful rights and benefits

VIETMEC values and continuously improves employee compensation policies, creating favorable conditions for employees to work with peace of mind and long-term commitment. Employees receive wages and bonuses in accordance with regulations and based on publicly available, transparent performance evaluation criteria.

The Company has developed a compensation, bonus, and welfare system appropriate to each stage of development, ensuring fairness and proportionality to individual contributions, while remaining competitive in the labor market.

In addition to internal training programs, the Company also promotes talent development by providing scholarships for students from top-tier universities. VIETMEC has expanded cooperation with universities and colleges in student recruitment, training, scientific research, technology transfer, and recruitment in fields such as pharmaceuticals, communications, finance & accounting, manufacturing, and product distribution.

Such cooperation agreements help strengthen ties between businesses and educational institutions, enabling students to access scholarships, internships, and employment opportunities after graduation.

IV. Investment and Project Implementation

Several ongoing investment items, including the production lines for oncology drugs and infusion solutions, are currently behind schedule. In 2024, the Company engaged in discussions with international consultants and potential partners to assess the possibility of upgrading the production lines to meet EU-GMP standards. As a result, project timelines were delayed to allow for negotiations. Adjustments to equipment, site layout, personnel, and processes will be made to align with EU-GMP requirements. If successful, this will represent a major breakthrough in the Company's investment activities.

Regarding herbal cultivation projects: Four cultivation areas in Phu Tho Province Van Mieu, Kim Thuong, Thuong Cuu, and Thu Ngac have been planted. Technical staff are monitoring these areas, collecting samples for factory testing, and making necessary adjustments to ensure high yield and quality of harvested medicinal

herbs in the near future.

❖ **Environmental and Social Responsibility**

Viet Nam Medicinal Materials Joint Stock Company has effectively implemented environmental protection measures in its business operations; conducted regular environmental monitoring; and proactively reported and submitted information to the competent authorities as prescribed by law. Waste is classified and treated appropriately in accordance with regulations.

The Company always upholds the spirit of mutual support and compassion, aiming to contribute to community development through practical activities such as giving gifts to disadvantaged patients, donating funds to children in difficult circumstances, awarding scholarships to pharmacy students, and supporting the construction of martyrs' cemeteries.

In 2024, Viet Nam Medicinal Materials Joint Stock Company was among the top five enterprises with the highest level of contribution and sponsorship for the 18th “Spring for Children” program, with a sponsorship amount of VND 5 billion. In the same year, VIETMEC was also recognized as a notable enterprise for its active contributions to child welfare initiatives. On the afternoon of February 19, 2024, a representative of the Company, along with representatives of other outstanding enterprises, participated in the “Gratitude to Golden Hearts” event at the Presidential Palace and was awarded a certificate of commendation.

PART II

BOARD OF DIRECTORS’ ACTIVITIES IN 2024

I. Results of the Board of Directors’ Activities in 2024

In accordance with the Law on Enterprises, the Company Charter, Internal Governance Regulations, and the Operating Regulations of the Board of Directors (BOD), the BOD convened 34 meetings in 2024 and issued 37 resolutions. These resolutions were passed with a high level of consensus, focusing on matters under the BOD’s authority. All resolutions were issued promptly, based on actual business conditions, ensuring that the Company remained aligned with its strategic direction and strived to fulfill the targets approved by the General Meeting of Shareholders (GMS).

Attendance rate of BOD members during the 2021–2026 term in 2024:

No.	BOD Member	Meetings Attended	Attendance Rate	Reason for Non-attendance
1	Mr. Nguyen Van Cai	33/33	100%	
2	Mr. Vu Thanh Trung	33/33	100%	
3	Ms. Nguyen Thi Ha	29/33	88%	Attended meetings after appointment on May 31, 2024
4	Mr. Tran Binh Duye	05/33	15%	Did not attend meetings after dismissal on May 31, 2024
5	Mr. Pham Hoang Linh	05/33	15%	
6	Ms. Doan Thi Thu Hoai	05/33	15%	

The BOD, in coordination with the Executive Board, implemented the 2024 GMS resolutions, including:

- Executing the 2024 business plan;
- Selecting the Company's audit firm (Branch of International Auditing and Valuation Company Limited) to conduct the 2024 financial statement audit;
- Issuing shares to pay dividends for the year 2022;
- Amending the Company Charter;
- Signing a service contract and working with Tue Minh Accounting Services Co., Ltd. to conduct internal audits of four departments: Product R&D, Phu Tho Plant operations, Finance & Accounting, and Sales & Business operations; compiling 8 thematic reports.
- Cooperating in the investment project "Investment and Support for the Development of Rare Medicinal Herb Cultivation Zones" in Bac Ai District, Ninh Thuan Province.

The BOD frequently monitored the situation and urged the implementation of its resolutions, coordinating in a timely manner with the Executive Board to take appropriate measures to support business operations.

Unimplemented item in 2024: The public offering of shares to existing shareholders was not executed due to market volatility. Since September 2024, the share price dropped below VND 10,000/share, while the expected offering price was VND 10,000/share. As the price was unattractive, the Company did not proceed with the issuance in 2024.

Additionally, the BOD collaborated closely with the Supervisory Board to enhance supervision and ensure strict compliance with the law and the Company Charter.

The Board of Directors regularly reviewed and urged the implementation of its Resolutions and coordinated in a timely manner with the Executive Board to adopt appropriate measures aligned with the Company's business operations.

In addition, the Board of Directors collaborated with the Supervisory Board to strengthen the supervisory, management, and guidance functions, ensuring compliance with legal regulations and the Company Charter.

II. Performance of Board Members in 2024.

- Each member of the Board of Directors was assigned specific responsibilities according to their respective areas to examine matters under the authority of the Board, and to supervise, guide, and urge the General Director to implement Resolutions according to the assigned domains;
- In 2024, all Board members fully participated in BOD meetings with a high sense of responsibility, integrity, and diligence, demonstrating leadership capabilities for the benefit of shareholders and the sustainable development of the Company;
- The Chairman of the BOD fulfilled his duties in accordance with the Law on Enterprises, the Law on Securities, the Company Charter, and the BOD Operating Regulations, including formulating and executing the annual work plan, delegating responsibilities among BOD members, organizing meetings, collecting written opinions, and issuing Resolutions and Notices of the BOD;
- The Independent Board Member made significant contributions to the improvement of the Company's internal governance system and jointly managed and supervised business operations with the Board of Director;
- The BOD members assigned to oversee specific business segments made great efforts to fulfill their designated duties effectively.

III. Results of Supervision over the General Director

In 2024, the General Director fully complied with the legal obligations related to reporting, explanation, and information disclosure. The Executive Board delegated tasks clearly among its members and operated with a high level of cooperation and consensus toward achieving the strategic goals set by the BOD.

The Executive Board regularly and proactively reported on the Company's business performance, as well as difficulties and obstacles encountered during management. The Board of Directors and the Executive Board worked together to promptly and flexibly propose effective solutions suited to the pharmaceutical industry context in 2024. The Executive Board also strictly followed Resolutions passed by the GMS and BOD, maintaining its leadership role in motivating and guiding the Company's employees to overcome challenges and implement the 2024 business plan, develop the market, secure employment for workers, and increase both revenue and profit.

The General Director also made notable improvements in operational management, issuing new regulations on human resources management and reporting procedures, as well as implementing IT applications for production operations, organizational governance, professional sales management, and transparent financial and accounting control.

Unimplemented item in 2024: Establishment of Viet Nam Medicinal Materials JSC Branch in Thanh Hoa Province. Reason: No suitable location has been identified.

IV. Remuneration and Operating Expenses of the Board of Directors

- The operating expenses of the Board of Directors (BoD) have been carried out by the current regulations issued by the Company;
- In 2024, the Company paid remuneration to BoD members as approved.

No.	Name	Position	Remuneration (VND)	Salary & Bonus (VND)
1	Mr. Tran Binh Duyen	Chairman of the BoD (Dismissed on May 10, 2024)	100,000,000	45,603,810
2	Mr. Vu Thanh Trung	Member of the BoD	104,000,000	692,926,750

3	Mr. Nguyen Van Cai	Chairman of the BoD	110,000,000	0
4	Mr. Pham Hoang Linh	Member of the BoD (Dismissed on May 10, 2024)	80,000,000	0
5	Ms. Doan Thi Thu Hoai	Member of the BoD (Dismissed on May 10, 2024)	40,000,000	222,204,218
6	Ms. Nguyen Thi Ha	Member of the BoD (Appointed on May 31, 2024)	24,000,000	0
Total			458,000,000	960,734,778

PART III

ORIENTATION FOR THE BOARD OF DIRECTORS IN 2024

I. Proposed Targets

To continue the journey of sustainable and in-depth development in 2025, the Board of Directors will focus on accelerating the implementation of investment projects, basing decisions on actual market conditions and relevant factors in the Company's business operations. The Board aims to meet the following planned targets:

Indicator	Unit	2025 Plan
Net Revenue	VND billion	1,560
Total Pre-Tax Profit	VND billion	62
Expected Dividend Payout	%	0

II. Governance Orientation for 2024

To achieve the business targets and realize the long-term development strategy, the Board of Directors and the Executive Board have outlined the following directions for 2024:

- Continue to improve corporate governance and executive management, human resource development, and build a transparent and reputable brand image; establish a robust internal system to enhance the performance of all team members;
- Continue implementing efficient investment projects to enhance production capacity; improve labor productivity and optimize inventory management.
- Strengthen investment in research and development of strategic, high-potential, and high-value products to boost the Company's position in the domestic market and promote exports to new markets;
- Closely supervise and promptly direct the Executive Board's operations; maintain healthy financial standing and explore the application of financial risk management tools.

III. Key Strategic Solutions

❖ *For Product Research and Development*

Increase investment in strategic products with high potential and value, elevate the Company's market position domestically, and promote export activities to new markets.

❖ *For Business Operations*

- Maintain and enhance stable bidding operations to preserve traditional markets for herbal medicine and Oriental medicine products; promote and expand OTC channel sales and aggressively implement sales programs at retail points to increase market coverage;
- Implement suitable policies to boost sales to new customers and markets while reducing sales costs in existing markets, aiming to increase revenue and improve profit margins;
- Expand and develop the sales system, improve the skills of medical sales representatives, and focus on building a portfolio of strategic products with high revenue and profitability, maximizing competitive advantages;
- Strengthen marketing activities to promote products and corporate image,

enhancing market position and industry reputation.

❖ ***For Production Activities***

- Review and improve procurement and raw material inventory policies to mitigate the effects of price volatility and enhance product competitiveness;
- Strictly adhere to current GMP and SOP standards and complete annual production plans to ensure on-time delivery and consistent product quality.

❖ ***For Investment Activities***

- Timely upgrade and repair of existing production lines to improve production capacity and efficiency.
- Continue working with partners to reach an agreement and complete EU-GMP-standard production lines for cancer treatment drugs and infusion solutions.
- Conduct feasibility studies for the VIETMEC Medicinal Herbs and Medical Equipment Plant and the VIETMEC Pharmaceutical Plant at Vạn Xuân Industrial Cluster, Tam Nông District, Phú Thọ Province to meet the growing demand of the domestic market.
- Continue to apply for investment licenses and implement projects approved by the General Meeting of Shareholders.

The content above is the full report the Board of Directors submitted to the General Meeting of Shareholders for approval!

Despite facing challenges now and in the coming years, the Board of Directors firmly believes that the Company will accomplish its goals and tasks through collective effort, unity, and responsibility.

Sincerely!

**ON BEHALF OF
THE BOARD OF DIRECTORS**



NGUYEN VAN CAI

**REPORT OF THE SUPERVISORY BOARD
AT THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS**

To: Esteemed Shareholders of Viet Nam Medicinal Materials Joint Stock Company

Pursuant to The Law on Enterprises No. 59/2020/QH14 dated June 17, 2020 issued by the National Assembly of the Socialist Republic of Vietnam;

Pursuant to The Law on Securities No. 54/2019/QH14 dated November 26, 2019 issued by the National Assembly of the Socialist Republic of Vietnam;

Pursuant to The Charter of Viet Nam Medicinal Materials Joint Stock Company;

Pursuant to The Operating Regulations of the Supervisory Board;

The Supervisory Board respectfully submits its report on the activities during the year as follows:

I. Members of the Supervisory Board in 2024

In 2024, the Supervisory Board of Viet Nam Medicinal Materials Joint Stock Company consisted of 03 members. Details are as follows:

No.	Full name	Position	Start Date/End Date of Supervisory Board Members
1	Nguyen Thi Tuyet Mai	Head of Supervisory Board	Dismissed on May 31, 2024
2	Duong Thi Ngoc	Member of Supervisory Board	Dismissed on May 31, 2024
3	Tran Thi Thanh Tam	Member of Supervisory Board	Dismissed on May 31, 2024

4	Nguyen Diep Khanh Linh	Head of Supervisory Board	Appointed on May 31, 2024
5	Bui Cong Tuan	Member of Supervisory Board	Appointed on May 31, 2024
6	Đang Thi Khanh Ngan	Member of Supervisory Board	Appointed on May 31, 2024

- Meeting of the Supervisory Board:

No.	Members	Number of Meetings Attended	Attendance Rate	Reason for Not Attending Meetings
1	Nguyen Diep Khanh Linh	5/7	72%	Attended meetings held after May 31, 2024
2	Bui Cong Tuan	5/7	72%	
3	Đang Thi Khanh Ngan	5/7	72%	
4	Nguyen Thi Tuyet Mai	2/7	28%	Did not attend meetings after May 31, 2024.
5	Duong Thi Ngoc	2/7	28%	
6	Tran Thi Thanh Tam	2/7	28%	

II. Activities of the Supervisory Board

- The Supervisory Board conducted supervision of the operations and compliance with the provisions of law and the Company's Charter by the Board of Directors and the Executive Board in managing and administering the Company.
- Examined and monitored the implementation of the Company's business plan in accordance with the resolutions of the General Meeting of Shareholders.
- Examined and monitored the issuance of resolutions and decisions by the Board of Directors and the Executive Board.
- Supervised the compliance with legal regulations on information disclosure by the Company.

III. Inspection and Supervision Results:

1. Review of the 2024 Financial Statements:

- Business performance results of the Company in 2024:

Unit: VND billion

Indicator	Unit	2024 Actual	Compared to 2023		Compared to 2024 Plan	
			2023 Actual	% increase/ decrease	2024 Plan	% Plan achieved
Net Revenue	VND billion	1,579.97	1,481.72	6.63%	1,200	131.66%
Total profit before tax	VND billion	55.40	49.50	11.91%	59.7	92.80%
Total profit after tax	VND billion	47.88	43.16	10.92%	49.55	96.73%
Basic earnings per share	VND	1,119	1,211	-	1,158	96.63%

- In 2024, the Company's production and business activities faced many difficulties due to the general economic fluctuations in Vietnam and globally. However, with the efforts of the Board of Directors, the Executive Board, all employees of the Company, and the support and cooperation of customers, the Company exceeded the revenue plan by 131.66% and fulfilled 96.73% of the profit plan. The main reason was the restructuring of the sales mechanism, which led to a significant reduction in total selling expenses from VND 25.67 billion in 2023 to VND 11.25 billion in 2024, equivalent to a 56.17% decrease. In addition, effective loan management contributed to a 20.6% reduction in financial expenses compared to 2023.
- Financial management was carried out in compliance with current regulations and policies, and all tax obligations to the State were fully fulfilled. The Company also improved professional skills for its staff.
- The Company distributed dividends in the form of shares to shareholders in 2024.

2. Supervision Results of the Board of Directors and Executive Board:

- In 2024, the Board of Directors performed its functions and responsibilities by directing and supervising the activities of the Executive Board to ensure the safe and efficient operation of the Company.
- The Executive Board operated the Company's business activities in accordance with the operating regulations of the Executive Board, in compliance with the resolutions of the General Meeting of Shareholders, and in accordance with resolutions and decisions of the Board of Directors.
- All Company activities complied with the provisions of the Law on Enterprises and the Company's Charter.

IV. Evaluation of the Coordination between the Supervisory Board and the Board of Directors, Executive Board, and Shareholders:

- The coordination between the Supervisory Board, the Board of Directors, and the Executive Board was implemented closely and in alignment with the resolutions of the General Meeting of Shareholders.

V. SUPERVISORY BOARD'S OPERATION PLAN FOR 2025

No.	Plan Activities	Timeline
1	Attend the 2024 Annual General Meeting of Shareholders + Attend the AGM. + Present the 2024 activity report, 2025 orientation plan, and recommendations before the AGM. + Supervise the activities of the Board of Directors and the General Director in corporate governance and administration.	May 2025
2	Review the Company's investment, construction, and project implementation activities.	Quarterly
3	Examine the reasonableness, legality, truthfulness, and prudence in business operations management, and the consistency and appropriateness of accounting, statistics, and financial reporting practices.	Quarterly
4	Appraise the accuracy, legality, and truthfulness of the Company's annual and semi-annual business performance and financial statements; review the Board of Directors' management report;	Semi-annual

	present appraisal reports at the AGM; review related-party contracts/transactions under the approval authority of the Board of Directors or the General Meeting of Shareholders and provide recommendations where necessary.	
5	Review and evaluate the effectiveness and efficiency of the Company's internal control, risk management, and early warning systems.	Quarterly
6	Examine accounting books, records, and other corporate documents, as well as the Company's governance and management practices, when deemed necessary or as requested by the General Meeting of Shareholders or shareholders/group of shareholders as stipulated in Clause 2, Article 115 of the 2020 Law on Enterprises.	Quarterly / Semi-annual / Annual / Ad hoc
7	Monitor the Board of Directors and Executive Board in: <ul style="list-style-type: none"> - Implementing the Company's strategies approved by the General Meeting of Shareholders and the Board of Directors - Executing the 2024 business plan - Utilizing shareholders' capital effectively - Complying with the Company's Charter, the Law on Securities, the Law on Enterprises, and applicable laws. 	Monthly
8	Coordinate with the Legal Department in handling letters of complaint, denunciations within its jurisdiction (if any)	As arising
9	Nominate members to attend training courses, professional development sessions, and policy update briefings	As arising
10	Monitor the performance of capital management functions and the protection of shareholders' rights	Quarterly
11	Perform other tasks assigned by the General Meeting of Shareholders	Upon specific assignment

VI. Remarks and Recommendations:

- Through supervisory activities in 2024, it is observed that the Company's production and business operations were conducted safely and in compliance with legal regulations, in accordance with the orientations and resolutions of the General

Meeting of Shareholders.

- The Supervisory Board recommends that the General Meeting of Shareholders authorize the Board of Directors to select an independent audit firm qualified under applicable regulations to audit the financial statements of Viet Nam Medicinal Materials Joint Stock Company for the fiscal year 2025.
- The Supervisory Board recommends that the General Meeting of Shareholders authorize the Board of Directors to select an audit firm to conduct the internal audit for the financial year.
- The Supervisory Board recommends that the Executive Board proactively implement market-related tasks to expand the Company's product consumption market and sales channels.
- The Supervisory Board recommends that the Executive Board closely follow specific regulations of the pharmaceutical industry, tax laws, labor laws, etc., to gradually restructure the enterprise during the development process.
- It is recommended to strictly control the storage and circulation of documents, and ensure proper authorization from the Management Board during the operation of business, finance, and investment activities,...

The Supervisory Board recommends that the Executive Board proactively seek and invite new customers to use the Company's services.

The above is the full report of the Supervisory Board.

Respectfully submitted.

Recipients:

- General Meeting of Shareholders
- Board of Directors
- Archived: Supervisory Board

Phu Tho, June 16th 2025

ON BEHALF OF

THE SUPERVISORY BOARD

Head of the Supervisory Board



Nguyễn Diệp Khanh Linh

**REGULATIONS ON THE ORGANIZATION
OF THE 2025 AGMS**

Chapter I

GENERAL PROVISIONS

Article 1. Scope of application

These regulations on the organization of the General Meeting of Shareholders are used for the organization of the 2025 Annual General Meeting of Shareholders (the General Meeting) of Vietnam Medicinal Materials Joint Stock Company (DVM).

Article 2. These regulations specifically stipulate the rights and obligations of the parties participating in the General Meeting, as well as the conditions and procedures for conducting the General Meeting.

Article 3. Shareholders and participating parties are responsible for complying with the provisions of these regulations.

Chapter II

RIGHTS AND OBLIGATIONS OF PARTIES PARTICIPATING IN THE AGMS

Article 4. Rights and obligations of shareholders attending the General Meeting

4.1. Conditions for attending the General Meeting:

All shareholders owning DVM shares according to the shareholder list finalized by the Vietnam Securities Depository and Clearing Corporation on May 19, 2025, or individuals/organizations duly authorized to attend.

4.2. Rights and obligations of eligible shareholders attending the General Meeting:

- a. Shareholders or authorized persons (hereinafter referred to as shareholders) attending the General Meeting must bring the following documents:
 - Valid identity card or passport;
 - Power of Attorney (in case of being authorized to attend the General Meeting).

(If the shareholder is an individual, the Power of Attorney must be signed by that

shareholder. If the shareholder is a legal entity/organization, the Power of Attorney must be sealed and signed by the legal representative of that legal entity/organization).

After presenting the above documents to the shareholder qualification verification committee, shareholders attending the General Meeting will receive a VOTING CARD, a VOTING SLIP, and an ELECTION BALLOT (stating the shareholder code and the number of voting shares of that shareholder*). The value of the Voting Card, Voting Slip, and Ballot of the shareholder attending the General Meeting corresponds to the total percentage of voting shares that the shareholder owns or is authorized to represent as registered for attendance at the General Meeting, out of the total voting shares of the shareholders attending the General Meeting.

*(*One share corresponds to one vote)*

- b. Shareholders may authorize in writing an individual/organization to act on their behalf to attend and vote at the General Meeting of Shareholders.
- c. Shareholders attending the General Meeting who wish to express their opinions for discussion must obtain the consent of the Chairman, speak concisely, and focus on the key issues to be discussed, in accordance with the approved agenda of the General Meeting. Issues already raised by a previous speaker should not be repeated to avoid duplication. Shareholders attending the General Meeting may also write their questions on a Question Form and submit it to the Secretariat of the General Meeting.
- d. Shareholders have the right to vote on all matters within the authority of the General Meeting of Shareholders as stipulated in DVM's Charter.
- e. Shareholders attending the General Meeting, after hearing the reports on the matters to be approved, will discuss them together and approve them by voting.
- f. During the General Meeting, shareholders must follow the guidance of the Presidium, behave courteously and respectfully, and maintain order.
- g. Shareholders arriving after the General Meeting has commenced, after completing the registration procedures, are allowed to attend and participate in voting on the remaining matters requiring a vote according to the approved agenda of the General Meeting. In such cases, the validity of votes already cast will not be affected.

Article 5. Rights and obligations of the Chairman and the Presidium

- 5.1. The Chairman of the Board of Directors (BOD) is the Chairman, or delegates another Board of Directors member to act as the Chairman of the General Meeting.
- 5.2. The Presidium, elected at the General Meeting, has the following duties:
 - a. To direct the activities of the General Meeting according to the approved agenda. To carry out necessary tasks to ensure the General Meeting of Shareholders proceeds in an orderly manner and reflects the wishes of the majority of attending shareholders;

- b. To guide delegates and the General Meeting in discussions;
- c. To present drafts and necessary contents for the General Meeting to vote on;
- d. To answer questions raised by the General Meeting.

Article 6. Rights and Obligations of the Shareholder Qualification Verification Committee

The Shareholder Qualification Verification Committee for the Annual General Meeting of Shareholders is established by the Chairman of the DVM Board of Directors or a person authorized by the Chairman of the Board of Directors. The Shareholder Qualification Verification Committee receives documents from attending shareholders to verify their validity and cross-reference them with the list of shareholders eligible to attend, as finalized on May 19, 2025; distributes documents, VOTING CARDS, VOTING SLIPS, ELECTION BALLOTS; and reports to the General Meeting on the results of shareholder qualification verification before the General Meeting officially commences.

Article 7. Rights and obligations of the General Meeting Secretariat

- 7.1. The Chairman introduces the General Meeting Secretariat, and the General Meeting votes to approve its establishment.
- 7.2. The General Meeting Secretariat performs supporting tasks as assigned by the Chairman, including:
 - a. Fully and accurately recording the contents of the General Meeting;
 - b. Assisting the Presidium in announcing the draft Minutes and Resolution of the General Meeting and notifications from the Presidium to shareholders when requested;
 - c. Receiving question slips from shareholders.

Article 8. Rights and Obligations of the Vote Counting Committee

- 8.1. The Chairman introduces the Vote Counting Committee, and the General Meeting votes to approve its establishment.
- 8.2. The Vote Counting Committee has the following duties:
 - a. To introduce the content and method for filling out voting slips and election ballots;
 - b. To supervise the voting of shareholders at the General Meeting;
 - c. To compile the number of voting shares for each agenda item;
 - d. To announce the results to the Chairman, the General Meeting Secretariat, and to publicize the voting results before the General Meeting.

Chapter III

CONDUCT THE GENERAL MEETING

Article 9. Conditions for conducting the General Meeting

The General Meeting of Shareholders shall be convened when the number of attending shareholders represents over 50% of the total voting shares according to the shareholder list of Viet Nam Medicinal Materials Joint Stock Company, finalized by Vietnam Securities Depository and Clearing Corporation on May 19, 2025.

Article 10. Order of the General Meeting

- 10.1. All shareholders attending the General Meeting must be appropriately dressed.
- 10.2. Shareholders entering the meeting room must sit in the designated positions or areas specified by the General Meeting Organizing Committee. Compliance with the directives of the Chairman and the General Meeting Organizing Committee is required.
- 10.3. No smoking in the meeting room.
- 10.4. No private conversations or use of mobile phones during the General Meeting. Cellphones must be turned off or set to silent mode.

Article 11. Methods for voting and electing on issues at the General Meeting

All agenda items of the General Meeting must be approved by openly seeking the voting opinions of all shareholders attending the General Meeting using **VOTING CARDS, VOTING SLIPS, and ELECTION BALLOTS** according to the number of shares owned/represented and/or authorized. Each shareholder will receive 01 VOTING CARD, 01 VOTING SLIP, and 01 SUPERVISORY BOARD ELECTION BALLOT, which will include: Shareholder Code; Number of voting shares (owned/represented and/or authorized) of the shareholder, and bear the DVM seal.

11.1. VOTING CARD: printed on **white paper**, used for voting on the following contents:

- a. Approving the Regulations on the Organization of the 2025 Annual General Meeting of Shareholders;
- b. Approving the composition of the Presidium of the General Meeting;
- c. Approving the Agenda;
- d. Approving the composition of the General Meeting Secretariat and the Vote Counting Committee;
- e. Approving the Election Regulations for additional Supervisory Board members for the remainder of the 2021-2026 term;
- f. Approving the dismissal of Supervisory Board members (due to resignation);
- g. Approving the list of candidates for additional Supervisory Board members for the remainder of the 2021-2026 term;
- h. Approving the Meeting Minutes and the Resolution of the General Meeting of Shareholders;

- i. Approving other matters (if any).

11.2. VOTING SLIP: printed on white Yellow, used for voting on the following contents:

- a. Approving the 2024 operational report of the Company's Board of Directors; the direction and operational plan of the Board of Directors for 2025;
- b. Approving the 2024 operational report of the Supervisory Board and the plan for 2025;
- c. Approving the audited 2024 financial statements;
- d. Approving the report on the audited use of owner's contributed capital with the capital contribution from the issuance of 8,650,000,000 shares up to December 31, 2024, as audited;
- e. Approving the 2024 profit distribution and dividend plan, and the 2025 profit distribution and dividend plan;
- f. Approving the salary, bonuses, and remuneration payments for 2024 and the remuneration plan for 2025 for the Board of Directors and the Supervisory Board;
- g. Approving the selection of the audit firm for the 2025 financial statements;
- h. Approving the plan to issue shares to pay dividends to existing shareholders;
- i. Approving the plan for offering shares to increase charter capital;
- j. Approving other contents falling under the authority of the General Meeting of Shareholders (if any, according to the Meeting Agenda).

11.3. SUPERVISORY BOARD ELECTION BALLOT: printed in Green, used for electing and consolidating personnel for the Supervisory Board members for the remainder of the 2021-2026 term.

Article 12. Approval of the Resolution of the General Meeting of Shareholders

Resolutions of the General Meeting of Shareholders shall be approved in accordance with the provisions of DVM's Charter and the current Enterprise Law.

Chapter IV

CLOSING OF THE GENERAL MEETING

Article 13. Minutes and Resolution of the General Meeting of Shareholders

- 13.1. The Minutes and Resolution of the General Meeting of Shareholders must be completed and approved before the closing of the General Meeting.
- 13.2. The Minutes and Resolution of the General Meeting of Shareholders must be kept at the Viet Nam Medicinal Materials Joint Stock Company.

Article 14. Enforcement effect

These Regulations, consisting of 14 (fourteen) Articles, shall be read publicly before the General Meeting of Shareholders and shall take effect immediately upon being approved by the 2025 Annual General Meeting of Shareholders.

**VIET NAM MEDICINAL MATERIALS
JOINT STOCK COMPANY
CHAIRMAN**



NGUYEN VAN CAI



**REGULATIONS ON
THE ELECTION OF ADDITIONAL SUPERVISORY BOARD MEMBERS
FOR THE REMAINDER OF THE 2021-2026 TERM**

The 2025 Annual General Meeting of Shareholders of Viet Nam Medicinal Materials Joint Stock Company will conduct the election of additional Supervisory Board members for the remainder of the 2021-2026 term according to the following content:

Article 1. Subjects of election

Shareholders holding voting shares and authorized representatives of shareholders holding voting shares (according to the Company's shareholder list finalized on May 19, 2025).

Article 2. Standards and conditions for Supervisory Board members

- Supervisory Board members must meet the standards and conditions stipulated in Article 169 of the Enterprise Law, the company's Charter, and must not fall into the following cases:
 - a) Working in the accounting and finance department of the company;
 - b) Being a member or employee of an auditing organization approved to audit the company's financial statements in the immediately preceding 03 years.

Article 3. Nomination, Candidacy for Supervisory Board Members, and Number of Members to be elected

3.1. Nomination of Supervisory Board Member Candidates

- A shareholder or group of shareholders owning 10% or more of the total common shares has the right to nominate or elect Supervisory Board members in accordance with the provisions of the Enterprise Law and the Charter.

3.2. Dossier for Candidacy and Nomination to the Supervisory Board

- Application for candidacy or nomination of a candidate for Supervisory Board membership;

- Group meeting minutes (in case of a group of shareholders making the candidacy/nomination);
 - Curriculum vitae personally filled out by the candidate (according to the template);
 - Valid copy of ID Card/Citizen ID/Passport;
 - Valid copy of the candidate's relevant degrees/certificates (if any).
- ❖ **Note:** *Individuals nominated or applying for the Supervisory Board must bear responsibility before the law and the General Meeting of Shareholders for the accuracy and truthfulness of the contents of their candidacy or nomination dossier.*

3.3. Number of Supervisory Board Members to be Elected

- The number of Supervisory Board members to be elected at the 2025 Annual General Meeting of Shareholders for the remainder of the 2021-2026 term is 01 (one) member.

Article 4. Ballot and Instructions for Completion

4.1. List of Supervisory Board candidates

- Arranged in alphabetical order by name, with full name written on the ballot.

4.2. Ballot and Instructions for Completion

- The ballot is uniformly printed, showing the total voting rights according to the Shareholder Code;
- Each shareholder or authorized representative will receive 01 Supervisory Board election ballot according to their Shareholder Code (owned and authorized);
- In case of an error, the shareholder may request the Vote Counting Committee to exchange for other ballots;
- Shareholders must personally write the number of voting rights for each candidate in the blank box of that candidate on the ballot. In case of a valid authorization (with a power of attorney), the authorized person has full voting rights.

4.3. Cases of invalid ballots

- Ballots not in the Company's prescribed format, or without the Company's seal;
- Ballots that are crossed out, amended, have additional notes, or contain incorrect names, or names not belonging to the list of candidates approved by the General Meeting of Shareholders before voting takes place;

- Ballots where the total voting rights for the candidates exceed the total voting rights owned/authorized by that shareholder;
- Ballots without the signature of the shareholder/shareholder's representative.

Article 5. Election Method

- The voting for Supervisory Board members shall be conducted directly by secret ballot using the cumulative voting method.
- Each shareholder has a total number of votes corresponding to the total number of voting shares (including owned and authorized shares) multiplied by the number of Supervisory Board members to be elected.

(Details are in the attached Appendix on Cumulative Voting Guidelines)

Article 6. Vote Counting Committee, Voting and Vote Counting Principles

6.1. Vote Counting Committee

- The Vote Counting Committee is nominated by the Chairman and approved by the General Meeting of Shareholders;
- The Vote Counting Committee is responsible for submitting to the General Meeting of Shareholders for:
 - The approval of the Election Regulations;
 - The approval of the list of candidates;
 - The introduction of ballots, the distribution of ballots, and instructions on how to fill them out;
 - The counting of votes;
 - The announcement of election results before the General Meeting.
- Members of the Vote Counting Committee must not be on the list of nominees or candidates for the Supervisory Board.

6.2. Voting and Vote Counting Principles

- The Vote Counting Committee will inspect the ballot box in the presence of the shareholders.
- Voting begins when the distribution of ballots is completed and ends when the last shareholder casts their ballot into the ballot box.
- Vote counting must commence immediately after voting concludes.
- The vote counting results will be documented and announced to the General Meeting by the Head of the Vote Counting Committee.

Article 7. Principles of Cumulative Voting and Election of Supervisory Board Members

7.1 Cumulative Voting Principle:

As detailed in the Appendix on cumulative voting guidelines attached to these Regulations.

7.2 Principles for Election of Supervisory Board Members:

- Supervisory Board members are determined by the highest number of votes received, from highest to lowest, until the required number of members is filled.
- If two or more candidates receive the same number of votes for the last Supervisory Board member position, a re-election will be held among those candidates with an equal number of votes.

Article 8. Preparation and announcement of vote counting minutes

- After counting the votes, the Vote Counting Committee must prepare the vote counting minutes. The content of the minutes will include: total ballots issued, total ballots collected, number of valid ballots, number of invalid ballots; number of votes for each candidate for the Supervisory Board.
- The full text of the vote counting minutes must be announced before the General Meeting.

Article 9. Complaints regarding the election and vote counting will be resolved by the Chairman of the meeting and recorded in the minutes of the Shareholder Meeting.

This Regulation, consisting of 09 articles, has been read publicly before the General Meeting of Shareholders and shall take effect immediately upon being approved by the General Meeting of Shareholders.

**ON BEHALF OF THE
GENERAL MEETING OF SHAREHOLDERS**

CHAIRMAN



NGUYEN VAN CAI

ADDENDUM

INSTRUCTIONS FOR ACCUMULATING VOTES

(Attached to the Regulation on election of members of the Supervisory Board for the remaining term of 2021-2026 at the 2025 Annual General Meeting of Shareholders of DVM)

Suppose the General Meeting of Shareholders votes to elect 01 member of the Supervisory Board out of 03 candidates. Shareholder Nguyen Van A holds (including ownership and authorization) of 1,000,000 voting shares. At that time, the total number of voting rights of Nguyen Van A shareholders is:

$$1,000,000 \times 1 = 1,000,000 \text{ voting rights}$$

Shareholder Nguyen Van A can vote by the following method:

1. Put all 1,000,000 of their voting rights to 01 candidate for a member of the Supervisory Board.
 2. Equally divide 1,000,000 voting rights to 03 candidates for members of the Supervisory Board (equivalent to each candidate receiving $1,000,000/03$ voting rights of Nguyen Van A shareholder).
 3. Use 1,000,000 of their voting rights for each candidate for members of the Supervisory Board in different proportions, but the total number of voting rights for such candidates shall not exceed 1,000,000 voting rights.
- ***The vote of shareholder Nguyen Van A will be invalid in the following cases:***
 - The slip is not according to the form prescribed by the Company, without the seal of the Company.
 - The total voting rights for those candidates of Nguyen Van A shareholders exceeded 1,000,000 voting rights.
 - The crossed-out, corrected, added or incorrect name is not included in the list of candidates approved by the General Meeting of Shareholders before voting.
 - The ballot does not have the signature of the shareholder/shareholder's representative.
 - Other cases specified in the Election Regulation.

No.: 01/2025/TT-ĐHĐCĐ-DLVN

Phu Tho, June 16th 2025

PROPOSAL

On: Approval of annual contents under the authority of the General Meeting

To: The 2025 Annual General Meeting of Shareholders

Pursuant to the Law on Enterprise No. 59/2020/QH14 dated June 17, 2020;

Pursuant to the Law on Securities No. 54/2019/QH14 dated November 26, 2019;

Pursuant to the Charter of Organization and Operation of Viet Nam Medicinal Materials Joint Stock Company;

Pursuant to the Reports presented at the meeting;

Pursuant to the audited financial statements of the Company for 2024;

Pursuant to the business production plan for 2025.

The Company's Board of Directors respectfully submits the following contents for the General Meeting's approval:

1. Approval of the annual reports presented and discussed at the AGMS:

- Operational Report of the Company's Board of Directors for 2024; direction and operational plan of the Board of Directors for 2025.

(Details are in Report No. .../2025/BC-HĐQT-DLVN dated .../05/2025 of the Board of Directors, attached to this Report)

- Operational Report of the Supervisory Board for 2024 and plan for 2025.

(Details are in Report No. .../2025/BC-BKS-DLVN dated .../05/2025 of the Supervisory Board, attached to this Report).

2. Approval of Audited 2024 Financial Statements

- The Board of Directors (BOD) respectfully submits to the 2025 Annual General Meeting of Shareholders (AGM) for consideration and approval the Financial Statements for the fiscal year ended 31/12/2024 audited by International Valuation Company - The full version has been posted on the Company's website and disclosed information in accordance with regulations.



- The Company's 2024 financial data has been reviewed and audited by International Auditing and Valuation Co., Ltd. in accordance with the law on accounting;

(Details in the Financial Statements for the fiscal year ended 31/12/2024 have been audited by International Auditing and Valuation Co., Ltd. attached to this Report).

3. Approval of the audited report on the use of owner's contributed capital, with the capital contribution from the issuance of 8,650,000 shares up to December 31, 2024.

- The Board of Directors (BOD) respectfully submits the audited Report on the use of owner's contributed capital, specifically the capital contributed from the issuance of 8,650,000 shares up to December 31, 2024, audited by International Valuation Company, for the 2025 Annual General Meeting of Shareholders to review and approve. The full version has been published on the Company's website.

(Details are in the audited report on the use of owner's contributed capital, with the capital contribution from the issuance of 8,650,000 shares up to December 31, 2024, attached to this Report.)

4. Approval of the 2024 profit distribution and dividend plan, and the 2025 profit distribution and dividend plan.

4.1. Year 2024 profit distribution and dividend plan

No.	Indicators	Value
1.	Profit before tax in 2024:	55,401,459,321 VND
2.	Profit after tax in 2024:	47,874,884,656 VND
3.	Appropriations for Company funds (from PAT):	2,872,493,079 VND
	a. Quỹ đầu tư và phát triển (trích 5% LNST):	2,393,744,233 VND
	b. Quỹ khen thưởng phúc lợi (trích 1% LNST):	478,748,847 VND
4.	Retained profit after fund appropriations in 2024 (4=2-3):	45,002,391,577VND
5.	2024 Dividend: In 2024, the Board of Directors reported to the General Meeting an expected 2024 dividend rate of at least 10% of charter capital (as per the 2024 Company Board of Directors' Operational Report, Section 3, Part III, dated May 31, 2024). Based on the audited 2024 financial statements, the Company's 2024 profit after tax reached 47.88 billion VND, achieving 96.73% of the 2025 plan. Based on the current business operations, the Board of Directors proposes that the General Meeting approve an official 2024 dividend rate of 10%. Payment method: via shares.	10%/charter capital Equivalent to a total par value of shares issued: 42,779,916,000 VND

No.	Indicators	Value
	(Details of the 2024 share dividend issuance plan are in Report No. 01 dated June 16 th 2025 attached)	

4.2. Profit and dividend plan in 2025

No.	Indicators	Value
1.	Expected profit before tax in 2025:	66,800,000,000 VND
2.	Expected profit after tax in 2025:	53,440,000,000 VND
3.	Expected Deduction of the Company's funds (from LNST):	3,206,400,000 VND
	<i>a. Development and Investment Fund (5% of PAT):</i>	2,672,000,000 VND
	<i>b. Reward and Welfare Fund (1% of PAT):</i>	534,400,000 VND
4.	Expected retained profit after fund appropriations in 2025 (4=2-3):	50,233,600,000 VND
5.	2025 Dividend: The Board of Directors plans to propose to the 2026 Annual General Meeting of Shareholders the approval of dividend payments (if any) based on the actual business results achieved in 2025.	N/A

5. Approval of 2024 Remuneration, Bonuses, and Salaries Paid, and 2025 Remuneration Plan for the Board of Directors and Supervisory Board.

5.1. 2024 Remuneration Payments

- Remuneration for Board of Directors members: **418,000,000 VND**.
- Remuneration for Supervisory Board members: **180,000,000 VND**.
- Total salary and bonus of members of the Board of Management and Chief Accountant: **1,358,694,778 VND**.

5.2. 2025 Remuneration Plan

- Remuneration of members of the Board of Directors in 2025:

No.	Position	Remuneration/month (VND)
1	Chairman of the Board of Directors, Full-time Board Member, Independent Board Member	10,000,000
2	Part-time Member of Board of Director	0

- Remuneration of members of the Supervisory Board in 2025:

No.	Position	Remuneration/month (VND)
1	Head of Supervisory Board	8,000,000
2	Members of Supervisory Board	5,000,000

- Salaries and bonuses for Board of Directors members, Supervisory Board members, the Board of Management, and the Chief Accountant will be paid according to the Company's regulations and policies on salaries and bonuses.

6. Approval of the Selection of the Audit Firm for the 2025 Financial Statements.

Criteria for selecting an independent audit firm:

- The independent audit firm must meet all legal requirements.
- The firm must have a team of honest, reputable auditors who uphold professional ethics, possess high professional qualifications, and have many years of experience to ensure the quality and timely completion of financial statement audits.

Based on the above criteria for selecting an independent audit firm, and considering the results of the 2024 audit, to facilitate the 2025 audit, the Board of Directors respectfully proposes that the General Meeting of Shareholders continue to select International Auditing and Valuation Co., Ltd. as the audit firm for the 2025 financial statements.

7. Supplementing the Internal Corporate Governance Regulation with provisions on online meetings to ensure compliance with the current regulations, as follows:

Chapter II: GENERAL MEETING OF SHAREHOLDERS

Article 13. Procedures for the General Meeting of Shareholders (GMS) to pass resolutions via online conference

- 13.1. The Board of Directors shall decide to convene the GMS via online conference in cases of force majeure events as prescribed by law, such as war, natural disasters, epidemics, restrictive decisions by government authorities, or based on the company's need to organize the GMS in a way that facilitates full shareholder participation.
- 13.2. The Board of Directors is responsible for issuing and announcing the Meeting Regulations for the online conference format (including: method of online registration for the GMS; proxy authorization for online GMS participation; meeting conditions; methods of passing GMS resolutions online; methods of

online voting; online vote counting procedures; and notification of voting results).

- 13.3. Resolutions and Minutes of the online GMS shall be disclosed in accordance with applicable legal regulations.

Article 14. Procedures for the GMS to pass resolutions through a hybrid format (in-person combined with online conference):

- 14.1. The Board of Directors shall decide to convene the GMS in a hybrid format (in-person combined with online conference) in cases of force majeure events as prescribed by law, such as war, natural disasters, epidemics, restrictive decisions by government authorities, or based on the company's need to organize the GMS in a way that facilitates full shareholder participation.

- 14.2. The Board of Directors is responsible for issuing and announcing the Meeting Regulations for the hybrid format (including: method of registration for participation; proxy authorization; meeting conditions; methods of passing GMS resolutions; methods of voting; vote counting procedures; and notification of voting results).

- 14.3. Resolutions and Minutes of the hybrid GMS shall be disclosed in accordance with applicable legal regulations.

(All other contents remain unchanged from the Internal Corporate Governance Regulation dated July 2021)

We respectfully submit this matter for the General Meeting of Shareholders' consideration and approval.

**ON BEHALF OF
THE BOARD OF DIRECTORS**

Recipient:

- Annual General Meeting of Shareholders 2025;
- Save at PC.



NGUYEN VAN CAI

PROPOSAL

(On: Plan to issue shares to pay dividends to existing shareholders)

To: Shareholders of Viet Nam Medicinal Materials Joint Stock Company

- Pursuant to the Law on Enterprise No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020;
- Pursuant to the Law on Securities No. 54/2019/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, and its guiding implementation documents;
- Pursuant to Decree No. 155/2020/NĐ-CP dated December 31, 2020, of the Government, detailing the implementation of a number of articles of the Securities Law;
- Pursuant to the Charter on organization and operation of Viet Nam Medicinal Materials Joint Stock Company;
- Pursuant to Circular No. 118/2020/TT-BTC dated December 31, 2020, guiding certain contents on offering, issuing securities, public tender offers, share buybacks, public company registration, and public company status cancellation;
- Pursuant to the Proposal No. .../2025/TT-ĐHĐCĐ-DLVN dated .../05/2025 of the Board of Directors of Viet Nam Medicinal Materials Joint Stock Company regarding the approval of annual contents under the authority of the General Meeting.

The Board of Directors respectfully submits the following contents for the Company's General Meeting of Shareholders to consider and approve:

Based on the 2024 business performance results and the 2024 profit distribution and dividend plan in Section 5, Clause 4.1 of the Proposal No. .../2025/TT-ĐHĐCĐ-DLVN dated .../05/2025, we respectfully propose that the General Meeting of Shareholders approve the issuance of shares to pay dividends to existing shareholders as follows:

1. Plan to issue shares to pay dividends (according to Section 5, Clause 4.1 of the Proposal No. 01/2025/TT-ĐHĐCĐ-DLVN dated 16/06/2025)

Stock Name	:	Shares of Viet Nam Medicinal Materials Joint Stock Company
Stock Code	:	DVM
Types of securities	:	Common Stocks
Par value	:	10,000 VND/share

Number of shares outstanding	:	42,779,916 shares
Expected number of shares to be issued	:	4,277,991 shares
Total value of shares expected to be issued (at par value)	:	42,779,910,000 VND (In words: Forty-two billion seven hundred and seventy-nine million nine hundred and ten thousand VND)
Purpose of issuance	:	Issuing shares to pay dividends to existing shareholders
Issuance Method	:	Exercising rights Method
Issuance Beneficiaries	:	Existing shareholders of Viet Nam Medicinal Materials Joint Stock Company whose names appear on the final record date shareholder list for receiving dividend shares, as provided by Vietnam Securities Depository and Clearing Corporation (VSDC)
Issuance ratio (Number of shares expected to be issued/Number of outstanding shares)	:	10%/charter capital
Right exercise rate	:	10:1 (On the record date for finalizing the shareholder list to receive dividend shares, shareholders owning 01 share will receive 01 right to receive shares; for every 10 rights, 01 new share will be received)
Number of outstanding shares after issuance	:	47,057,907 shares
Expected charter capital after successful issuance	:	470,579,070,000 VND (In words: Four hundred and seventy billion five hundred and seventy nine million zero hundred and seventy thousand VND)
Method of handling fractional shares	:	<p>The number of additional shares issued as dividends, when distributed to shareholders, will be rounded down to the nearest whole unit. Fractional shares resulting from rounding down (if any) will be canceled.</p> <p><i>Example: On the record date for additional share issuance to pay dividends, shareholder Nguyen Van A currently owns 186 shares. Shareholder A will receive an additional $186 * 10/100 = 18.60$ shares. According to the fractional share handling method, the number of shares shareholder A receives after rounding down to the unit is 18 shares, and 0.60 fractional shares will be canceled.</i></p>

Source of capital for share dividend issuance	:	Undistributed profit after tax as of December 31, 2024, from the Company's audited 2024 financial statements
Transfer restrictions	:	- The right to receive dividend shares is not transferable - Shares issued as dividends are not subject to transfer restrictions.
Implementation timeline	:	Expected to be in 2025, with the Board of Directors deciding the specific time after receiving written notification from the State Securities Commission regarding the full receipt of the Company's share dividend issuance report documents.

2. Registration of additional securities and additional listing of newly issued shares:

The General Meeting of Shareholders approves the registration of additional shares at Vietnam Securities Depository and Clearing Corporation and the additional listing of shares on the Hanoi Stock Exchange (HNX) for the entire actual number of shares issued according to the aforementioned issuance plan, upon the conclusion of the issuance in accordance with current regulations.

3. Change in Charter Capital and Amendment of the Company Charter Regarding Charter Capital:

The General Meeting of Shareholders approves the adjustment of the charter capital item (Clause 1, Article 5) in the Company's Charter to correspond with the newly increased charter capital based on the actual issuance results.

4. Approval of authorized contents:

To submit to the General Meeting of Shareholders to assign and authorize the Board of Directors to decide all matters related to the issuance, including but not limited to the following contents:

- Proactively developing, finalizing, and explaining the share issuance report dossier to pay dividends as required by competent authorities, including amendments to the issuance plan, but excluding contents related to the expected number of shares to be issued and the exercise ratio;
- Selecting the specific time for the share issuance to pay dividends after receiving written notification from the State Securities Commission regarding the full receipt of the Company's share dividend issuance report documents, deciding the record date for shareholders to exercise their rights, ensuring compliance with legal regulations, and deciding the record date for shareholders to exercise rights related to the share issuance;
- Deciding and carrying out all necessary tasks and procedures related to: (i) issuing the amended Charter regulating the charter capital level in the Company's Charter after the completion of the issuance; (ii) registering changes to the Company's Business Registration Certificate; (iii) registering changes to the Company's Securities Registration Certificate at Vietnam Securities Depository and Clearing Corporation; and (iv)

registering additional listing of the Company's shares on the Stock Exchange and reporting to the General Meeting of Shareholders at the latest meeting.

- Other related tasks concerning the issuance, registration of changes to the securities registration certificate, and additional listing of newly issued shares.
- Depending on specific circumstances, the Board of Directors authorize/delegate the Chairman of the Board of Directors and/or the General Director to perform one or more of the above-mentioned tasks.

Respectfully submit to the General Meeting of Shareholders for consideration and approval of the above issue./.

Recipient:

- Annual General Meeting of Shareholders 2025;
- Member of the Board of Directors;
- Members of the Supervisory Board;
- Save at PC.

**ON BEHALF OF THE
BOARD OF DIRECTORS**



NGUYEN VAN CAI



**VIET NAM MEDICINAL MATERIALS
JOINT STOCK COMPANY**

SOCIALIST REPUBLIC OF VIETNAM

Independence - Freedom - Happiness

No.: 03/2025/TT-ĐHĐCĐ-DLVN

Phu Tho, June 16th 2025

PROPOSAL

(On: Plan for offering shares to increase charter capital)

To: Shareholders of Viet Nam Medicinal Materials Joint Stock Company

- Pursuant to the Law on Enterprise No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020;
- Pursuant to the Law on Securities No. 54/2019/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, and its guiding implementation documents;
- Pursuant to Decree No. 155/2020/NĐ-CP dated December 31, 2020, of the Government, detailing the implementation of a number of articles of the Securities Law;
- Pursuant to the Charter on organization and operation of Viet Nam Medicinal Materials Joint Stock Company;
- Pursuant to Circular No. 118/2020/TT-BTC dated December 31, 2020, guiding certain contents on offering, issuing securities, public tender offers, share buybacks, public company registration, and public company status cancellation;
- Considering the actual situation.

In 2024, the General Meeting of Shareholders approved the plan to issue shares to pay dividends in 2022 and the plan to offer additional shares to the public to existing shareholders according to the Resolution of the General Meeting of Shareholders No. 01/2024/NQ-ĐHĐCĐ-DLVN dated 31/05/2024 (the options are stated in Report No. 04/TTr-HDQT-DLVN dated 31/05/2024). However, due to unfavorable developments in the stock market, in 2024, the Company has only completed the plan to issue dividend-paying shares (*the Company's charter capital after completing the issuance of dividend-paying shares has increased from 356,500,000,000 to 427,799,160,000 VND*) and has not yet implemented the plan to publicly offer additional shares to existing shareholders right. Considering the upcoming production and business plan as well as the current structure of the Company's debt/capital, the Board of Directors realizes that the increase in the Company's charter capital is necessary, so it is submitted to the General Meeting of Shareholders for approval to continue implementing the Charter Capital Increase Plan. However, in order to ensure the feasibility and success of the offering, the Board of Directors submits to the General Meeting of Shareholders for approval the plan to increase charter capital, specifically as follows:

1. Approval of cancellation of public share offering to existing shareholders: The Board of Directors respectfully proposes that the Annual General Meeting approve the cancellation of the public share offering plan that was approved in Annual General Meeting Resolution No.

01/2024/NQ-ĐHĐCĐ-DLVN dated May 31, 2024 (details are in Report No. 04/TTr-HĐQT-DLVN dated May 31, 2024).

2. Approval of private placement plan for capital increase in 2025-2026:

- Demand to increase charter capital: Based on the audited financial statements for 2024, as of December 31, 2024, the Company's liabilities were 898,023,038,490 VND, corresponding to a Debt/Total Assets ratio of approximately 0.55 times. At the same time, the Company's loans and financial lease debt amounted to 766,552,527,334 VND, corresponding to a Loans and Financial Lease Debt/Total Liabilities ratio of 0.85 times. Although the Debt/Total Assets ratio is maintained at a reasonable level, a large portion of the liabilities consists of loans and financial lease debt. This indicates a low ability to utilize capital from suppliers and also poses potential financial risks, including significant fluctuations in financial costs (affecting business results) and liquidity risks during periods of unstable financial and credit markets. Accordingly, the Board of Directors plans to propose that the Annual General Meeting approves the use of 372,200,840,000 VND obtained from the private placement to increase charter capital for debt repayment, thereby reducing the Loans and Financial Lease Debt/Total Liabilities ratio to approximately 0.44 times and the Debt/Total Assets ratio to approximately 0.32 times. The Company believes this will positively impact financial balance and increase the stability of business operations.

- Implementation time: The implementation time is expected in 2025 and 2026 after the State Securities Commission has written approval and posted on the website of the State Securities Commission on the receipt of a complete dossier of registration for private placement of shares of the Company.

(The plan for private placement of shares to increase charter capital is attached to this Report)

Respectfully submit to the General Meeting of Shareholders for consideration and approval of the above issue./.

Recipient:

- Annual General Meeting of Shareholders 2025;
- Member of the Board of Directors;
- Members of the Supervisory Board;
- Save at PC.

ON BEHALF OF
THE BOARD OF DIRECTORS
CHAIRMAN



NGUYEN VAN CAI

PRIVATE PLACEMENT PLAN IN 2025-2026

(Attached to the Report No. 03/2025/TT-ĐHDCD-DLVN dated 16/06/2025 of the Board of Directors of Viet Nam Medicinal Materials Joint Stock Company on the plan for private placement of shares)

I. LEGAL BASIS

Enterprise Law No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020;

Securities Law No. 54/2019/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, and its guiding implementation documents;

Decree No. 155/2020/NĐ-CP of the Government dated December 31, 2020, detailing the implementation of a number of articles of the Securities Law;

Circular 118/2020/TT-BTC dated December 31, 2020, guiding certain contents on offering, issuing securities, public tender offers, share buybacks, public company registration, and public company status cancellation;

The Charter of Viet Nam Medicinal Materials Joint Stock Company (DVM);

DVM's audited 2024 financial statements;

DVM's business production and investment plan.

II. PRIVATE PLACEMENT PLAN

- | | | |
|--|---|--|
| 1. Stock Name | : | Shares of Viet Nam Medicinal Materials Joint Stock Company |
| 2. Stock Code | : | DVM |
| 3. Types of securities | : | Common Stocks |
| 4. Par value | : | 10,000 VND/share |
| 5. Offering method | : | Private placement |
| 6. Current charter capital | : | VND 427,799,160,000 |
| 7. Number of shares currently outstanding | : | 42,779,916 Shares |
| 8. Number of shares expected to be offered | : | 37,220,084 Shares |
| 9. Total value of shares expected to be offered (at par value) | : | 372,200,840,000 VND |
| 10. Expected charter capital after | : | VND 800,000,000,000 |

the offering

11. Purpose of the offering : To enhance capital capacity and supplement capital for the Company's business production activities.
12. Offering price : 10,000 VND/share
13. Principles/Basis for determining the offering price :
 - a. Determination principle
 - (i). Book value of Viet Nam Medicinal Materials Joint Stock Company shares as of December 31, 2024, on the consolidated audited financial statements for 2024:
$$\text{Book value per share (as of 31/12/2024)} = \frac{\text{Owner's Equity}}{\text{Total outstanding shares as of 31/12/2024}} = \frac{748,843,121,761}{42,779,916} = 17,505 \text{ VND/share}$$
 - (ii). The average closing price of DVM shares over the last 30 trading sessions (from March 28, 2025, to May 14, 2025) is 6,957 VND/share
 - b. Price determination: Although the book value of the Company's shares is 17,505 VND/share, the market price of DVM shares is currently below par value. Therefore, to ensure the success of the offering, the Board of Directors proposes an offering price of 10,000 VND/share.
14. Plan to ensure the maximum foreign ownership rate : To ensure compliance with regulations on foreign investor ownership ratios, all privately offered shares will be distributed to domestic investors.
15. Target Investors
 - a. Investor selection criteria
Investors purchasing privately offered shares must be Professional Securities Investors who meet the following criteria
 - Domestic organizations and individuals
 - Being professional securities investors as defined in Article 11 of the Securities Law No. 54/2019/QH14 dated November 26, 2019, and Clause 3, Article 1 of the amended and supplemented Law dated November 29, 2024
 - b. Number of investors: unlimited
 - c. Expected investors:
The General Meeting of Shareholders authorizes the Board of Directors to identify professional securities investors in accordance with current legal regulations, select professional securities investors to distribute the offered shares, and ensure compliance with

regulations on foreign investor ownership ratios and cross-ownership.

16. Method of handling unsold : If the number of shares offered under the approved remaining shares (if any) Plan is not fully subscribed by investors, the Board of Directors will continue to offer them to other professional securities investors (ensuring they still meet the Investor Selection Criteria in Clause 12 of this Article). If the Board of Directors still cannot find suitable investors, the Board of Directors will adjust down the total number of shares offered to match the actual number of shares distributed.
17. Transfer restrictions : Newly privately offered shares will be restricted from transfer for **01 (one) year** from the end of the offering, except for transfers between professional securities investors or those carried out pursuant to legally effective court judgments, arbitral awards, or inheritance as stipulated by law. The right to receive dividend shares is not transferable. Shares issued as dividends are not subject to transfer restrictions.
18. Expected Offering Period : The private placement to increase charter capital is expected to be carried out in 2025 and 2026, after the State Securities Commission approves in writing and posted on the website of the State Securities Commission on the receipt of a complete dossier of registration for private placement of shares of the Company.
19. Charter Amendment : To approve the increase in charter capital and amend the charter capital level stipulated in the Company's Charter according to the results of the private share offering for capital increase.

III. PLAN TO USE CAPITAL FROM THE OFFERING

All proceeds from the offering will be used to repay the Company's debts (*including, but not limited to, repayment of bank loans, payables to suppliers, other payables, etc.*). The General Meeting of Shareholders authorizes the Board of Directors to decide on a detailed capital utilization plan that is suitable for the Company's actual situation.

IV. PROPOSAL OF THE GENERAL MEETING OF SHAREHOLDERS TO AUTHORIZE THE BOARD OF DIRECTORS

The General Meeting of Shareholders authorizes the Board of Directors with full authority to decide and organize the implementation of all matters related to the share offerings to

increase charter capital as mentioned above (hereinafter referred to as "the offering"), including but not limited to the following tasks:

- Proactively developing, finalizing, and explaining the private placement report dossier for capital increase as required by competent authorities, including amendments to the offering plan, but excluding contents related to the expected number of shares to be offered, the exercise ratio, and the expected number of shares to be offered.
- Identifying professional securities investors; approving the list of professional securities investors eligible to purchase privately offered shares, determining the number of shares to be offered to each professional securities investor, and the implementation timeline; deciding on the plan for handling unsold shares (if any).
- The General Meeting of Shareholders authorizes the Board of Directors to develop a detailed capital utilization plan from the offering. Concurrently, the General Meeting of Shareholders authorizes the Board of Directors to adjust the Capital Utilization Plan from the offering to suit the Company's operations, carry out public disclosure procedures in accordance with regulations, and report to the General Meeting of Shareholders at the nearest meeting.
- Deciding and carrying out all necessary tasks and procedures related to: (i) issuing the amended Charter regulating the charter capital level in the Company's Charter after the completion of the offering; (ii) registering changes to the Company's Business Registration Certificate; (iii) registering changes to the Company's Securities Registration Certificate at Vietnam Securities Depository and Clearing Corporation; and (iv) registering additional listing of the Company's shares on the Stock Exchange and reporting to the General Meeting of Shareholders at the nearest meeting.
- Other issues related to the private placement of shares.

Respectfully submitted to the General Meeting of Shareholders for approval./.

(The remainder of this page is intentionally left blank)

PROPOSAL

On: Approval of resignation of Supervisory Board member and election of additional Supervisory Board Member for the remainder of the 2021-2026 term

To: Annual General Meeting of Shareholders 2025

Pursuant to the the Law on Enterprise No. 59/2020/QH14 dated June 17, 2020;

Pursuant to the Charter on Organization and Operation of Viet Nam Medicinal Materials Joint Stock Company;

Pursuant to the resignation letter of a Supervisory Board member submitted to the Board of Directors of Viet Nam Medicinal Materials Joint Stock Company;

Pursuant to the nomination and candidacy applications for Supervisory Board membership of Viet Nam Medicinal Materials Joint Stock Company for the remaining term of 2021-2026 from shareholders of Viet Nam Medicinal Materials Joint Stock Company;

The Board of Directors of Viet Nam Medicinal Materials Joint Stock Company respectfully requests the General Meeting of Shareholders to approve the following contents:

- 1. Approval of the dismissal of Supervisory Board members of Viet Nam Medicinal Materials Joint Stock Company (due to resignation) as follows:**

No.	Full name	Position
1	Ms. Nguyen Diep Khanh Linh	Head of the Supervisory Board

- 2. Approval of the election of 01 (one) additional Supervisory Board Member for the remainder of the 2021-2026 term of Viet Nam Medicinal Materials Joint Stock Company.**

As explained in Section 1, due to the resignation of a Supervisory Board member, to ensure the required number of Supervisory Board members for the remainder of the



2021-2026 term, the Company's Board of Directors respectfully proposes that the Annual General Meeting approve the election of an additional Supervisory Board member as follows:

- Elect 01 additional Supervisory Board member for the remainder of the 2021-2026 term.

Based on the compiled nomination and candidacy applications from shareholders, the Board of Directors respectfully proposes that the Annual General Meeting approve the following list of candidates for the additional Supervisory Board member election:

- List of candidates for the Supervisory Board:

No.	Full name	Nominated/Candidacy Position
1	Nguyễn Chí Hiếu	Member of the Supervisory Board
2	Member of the Supervisory Board

This matter is respectfully submitted to the General Meeting of Shareholders for consideration and approval.

**ON BEHALF OF
THE BOARD OF DIRECTORS
CHAIRMAN**

Recipient:

- Annual General Meeting of Shareholders 2025;
- Save at PC.



NGUYEN VAN CAI



MINUTES
ANNUAL GENERAL MEETING OF SHAREHOLDERS 2025
VIET NAM MEDICINAL MATERIALS JOINT STOCK COMPANY

I. COMPANY INFORMATION

1. Company name: Viet Nam Medicinal Materials Joint Stock Company
2. Business Registration Certificate No.: 0105196582 issued by the Department of Planning and Investment of Phu Tho Province for the first time on 16/03/2011, issued for the 27th time on 20/09/2024
3. Head office address: Zone 8, Phu Ninh commune, Phu Ninh district, Phu Tho province.

II. MEETING TIME AND VENUE

Time: The General Meeting commenced at 8:00 AM on June 16, 2025.

Location: Muong Thanh Luxury Phu Tho Hotel, Lot CC17, Hung Vuong Square, Gia Cam Ward, Viet Tri City, Phu Tho Province.

III. PARTICIPANTS

1. Members of the Company's Board of Directors, members of the Audit Committee, the Company's Board of Management, heads/deputy heads of Company departments, and members of the General Meeting Organizing Committee.
2. Shareholders whose names are on the consolidated list of securities owners finalized by Vietnam Securities Depository and Clearing Corporation (VSDC) on May 19, 2025, and their duly authorized representatives.
3. Representative of the audit firm for the Company's 2024 financial statements: International Auditing and Valuation Co., Ltd.
4. Invited partners of the Company.

IV. OPENING SESSION

1. To ensure the meeting proceeds in accordance with regulations, Ms. Dương Thị Thái – Head of the Shareholder Qualification Verification Committee, presented the report on the eligibility of shareholders attending the General Meeting:

As of 09:10 AM, there were **36** delegates (attending in person and via authorization) present, representing **21,904,594** shares, accounting for **51.2%** of the Company's total voting shares.

Pursuant to the Enterprise Law 2020 and the Company's Charter on Organization and Operation, Viet Nam Medicinal Materials Joint Stock Company is fully qualified to hold the 2025 Annual General Meeting of Shareholders.

2. On behalf of the Organizing Committee, Mr. Nguyen Minh Hai – Head of the Annual General Meeting Organizing Committee, introduced and invited the Presidium to officiate the General Meeting. The Presidium consists of the following members:

Mr. Nguyen Van Cai - Chairperson

Mr. Vu Thanh Trung - Member

Mrs. Nguyen Thi Ha - Member

3. The Chairman of the General Meeting introduced and invited the General Meeting Secretariat to their working positions. The Secretariat consists of:

Ms. Nguyen Ha Van - HR and Administration Specialist - Head of Department

Ms. Nguyen Thi Duyen - HR and Administration Specialist - Member

4. Approval of the meeting agenda

Mr. Nguyen Van Cai, on behalf of the Presidium, presented and sought the General Meeting's approval for the meeting agenda.

The agenda for the 2025 Annual General Meeting of Shareholders was approved by the General Meeting through a show of voting cards, with an affirmative vote reaching 100% of the total votes of all shareholders attending and voting in the meeting. The Meeting agenda includes the following main contents for discussion and approval:

Content 1: Approval of the 2024 operational report of the Company's Board of Directors; the direction and operational plan of the Board of Directors for 2025.

Content 2: Approval of the 2024 operational report of the Supervisory Board and the plan for 2025.

Content 3: Approval of the audited 2024 financial statements.

Content 4: Approval of the audited report on the use of owner's contributed capital, with the capital contribution from the issuance of 8,650,000 shares up to December 31, 2024.

Content 5: Approval of the 2024 profit distribution and dividend plan, and the 2025 profit distribution and dividend plan.

Content 6: Approval of the 2024 remuneration, bonuses, and salaries paid, and the 2025 remuneration plan for the Board of Directors and Supervisory Board.

Content 7: Approval of the selection of the audit firm for the 2025 financial statements.

Content 8: Approval of the plan to issue shares to pay dividends to existing shareholders.

Content 9: Approval of the plan for offering shares to increase charter capital.

Content 10: Consolidation of Supervisory Board members for the remainder of the 2021-2026 term.

5. On behalf of the Annual General Meeting Organizing Committee, Mr. Nguyen Minh Hai – Head of the Annual General Meeting Organizing Committee, presented and sought the Annual General Meeting's approval for the Regulations on the Organization of the 2025 Annual General Meeting of Shareholders of Viet Nam Medicinal Materials Joint Stock Company.

The Regulations on the Organization of the 2025 Annual General Meeting of Shareholders were approved by the Annual General Meeting through a show of voting cards, with an affirmative vote reaching 100% of the total votes of all shareholders attending and voting in the meeting.

6. Mr. Nguyen Van Cai, on behalf of the Presidium, introduced and sought the Annual General Meeting's approval for the members of the Vote Counting Committee, comprising:

Mr. Nguyen Giang Nam - Legal Executive - Head of Department

Ms. Duong Thi Thai - Deputy Manager HR and Administration - Member

Ms. Ta Thi Thuong - HR and Administration Specialist - Member

The composition of the Vote Counting Committee has been voted and approved by the General Meeting of Shareholders in the form of holding up voting cards with an approval rate of 100% of the total votes of all shareholders attending and voting in the meeting.

V. MEETING REPORT CONTENTS

1. The Presidium members successively presented the reports, submissions, and related contents to the General Meeting according to the agenda's sequence, including:
 - 1.1 Mr. Vu Thanh Trung – CEO cum Member of the BOD presented the content: "Approval of the 2024 operational report of the Company's Board of Directors; direction and operational plan of the Board of Directors for 2025."
 - 1.2 Ms. Nguyen Diep Khanh Linh – Head of the Supervisory Board presented the content: "Approval of the 2024 operational report of the Supervisory Board and the plan for 2025."
 - 1.3 Mr. Nguyen Van Cai – President of the BOD presented the content: "Approval of the audited 2024 financial statements."
 - 1.4 Mr. Nguyen Van Cai – President of the BOD presented the content: "Approval of the audited report on the use of owner's contributed capital, with the capital contribution from the issuance of 8,650,000 shares up to December 31, 2024."

- 1.5 Mr. Nguyen Van Cai – President of the BOD presented the content: "Approval of the 2024 profit distribution and dividend plan, and the 2025 profit distribution and dividend plan."
- 1.6 Mr. Nguyen Van Cai – President of the BOD presented the content: "Approval of the 2024 remuneration, bonuses, and salaries paid, and the 2025 remuneration plan for the Board of Directors and Supervisory Board."
- 1.7 Mr. Nguyen Van Cai – President of the BOD presented the content: "Approval of the selection of the audit firm for the 2025 financial statements."
- 1.8 Mr. Vu Thanh Trung – CEO cum Member of the BOD presented the content: "Approval of the plan to issue shares to pay dividends to existing shareholders."
- 1.9 Mr. Vu Thanh Trung – CEO cum Member of the BOD presented the content: "Approval of the plan for offering shares to increase charter capital."

2. Mr. Nguyen Van Cai – President of the BOD presented and sought the General Meeting's vote on the content: "Supplementing the Internal Corporate Governance Regulation with provisions on online meetings to ensure compliance with the current regulations".

(Contents: As per Report No. 01/2025/BC-HDQT-DLVN dated 16/05/2025)

The General Meeting unanimously approved the dismissal of the Supervisory Board members who submitted resignation letters and the election of additional Supervisory Board members for the remainder of the 2021-2026 term through a show of voting cards, with an affirmative vote reaching 100% of the total votes of all shareholders attending and voting in the meeting.

The General Meeting unanimously approved the Regulations for the election of Supervisory Board members for the remainder of the 2021-2026 term through a show of voting cards, with an affirmative vote reaching 100% of the total votes of all shareholders attending and voting in the meeting.

3. Mr. Nguyen Van Cai – President of the BOD presented and sought the General Meeting's vote on the content: "Consolidation of Supervisory Board members for the remainder of the 2021-2026 term," which included:

- 3.1 Introducing and seeking the 2025 Annual General Meeting's approval for the dismissal of Supervisory Board members and the election of additional Supervisory Board members for the remainder of the 2021-2026 term.
- 3.2 Presenting the Regulations for the election of Supervisory Board members for the remainder of the 2021-2026 term.
- 3.3 Guiding the General Meeting on how to conduct the election of Supervisory Board members for the remainder of the 2021-2026 term using cumulative voting and secret ballots.

The General Meeting unanimously approved the dismissal of the Supervisory Board members who submitted resignation letters and the election of additional Supervisory

Board members for the remainder of the 2021-2026 term through a show of voting cards, with an affirmative vote reaching 100% of the total voting shares present at the Meeting. The General Meeting unanimously approved the Regulations for the election of Supervisory Board members for the remainder of the 2021-2026 term through a show of voting cards, with an affirmative vote reaching 100% of the total votes of all shareholders attending and voting in the meeting.

4. Update on Meeting attendance registration

Ms. Duong Thi Thai, Head of the Shareholder Qualification Verification Committee, presented an updated report on the verification of shareholder eligibility to attend the General Meeting:

As of 10:10 A.M, the total number of attending shareholders was **37 delegates** representing **21,904,835 voting shares**, equivalent to **51.2%** of the Company's total voting shares.

After Ms. Duong Thi Thai, Head of the Shareholder Qualification Verification Committee, presented the updated results of shareholder eligibility verification, Mr. Nguyen Van Cai presided over the General Meeting for the casting of votes and ballots into the ballot box in accordance with the Regulations and invited the Vote Counting Committee to commence their work.

VI. DISCUSSION AND COMMENTS OF SHAREHOLDERS AT THE GENERAL MEETING

While the Vote Counting Committee was conducting the voting and election count, the Chairman of the General Meeting facilitated discussion and sought shareholder contributions.

The General Meeting conducted discussions between shareholders and the Presidium, with positive exchanges taking place, but no questions were raised by the shareholders.

After the Presidium addressed the questions, the General Meeting agreed with the explanations and had no further comments. The Chairman of the General Meeting then invited the Vote Counting Committee to present the voting/election results of the Meeting.

VII. VOTING RESULTS

Based on the Report from the Vote Counting Committee, the results of the General Meeting's votes are as follows:

1. Approved the 2024 operational report of the Company's Board of Directors; the direction and operational plan of the Board of Directors for 2025.

(Contents: As per Report No. 01/2025/BC-HĐQT-DLVN dated 16/06/2025)

- Valid: 21,904,835 voting shares, accounting for 100% of the total votes of all shareholders attending and voting in the meeting
- Invalid: 0 voting shares, accounting for 0% of the total votes of all shareholders attending and voting in the meeting

- Approve: 21,904,835 voting shares, accounting for 100% of the total votes of all shareholders attending and voting in the meeting
- Disapprove: 0 voting shares, accounting for 0% of the total votes of all shareholders attending and voting in the meeting
- Abstain: 0 voting shares, accounting for 0% of the total votes of all shareholders attending and voting in the meeting

2. Approved the 2024 operational report of the Supervisory Board and the plan for 2025.

(Contents: As per Report No. 02/2025/BC-BKS-DLVN dated 16/06/2025)

- Valid: 21,904,835 voting shares, accounting for 100% of the total votes of all shareholders attending and voting in the meeting
- Invalid: 0 voting shares, accounting for 0% of the total votes of all shareholders attending and voting in the meeting
- Approve: 21,904,835 voting shares, accounting for 100% of the total votes of all shareholders attending and voting in the meeting
- Disapprove: 0 voting shares, accounting for 0% of the total votes of all shareholders attending and voting in the meeting
- Abstain: 0 voting shares, accounting for 0% of the total votes of all shareholders attending and voting in the meeting

3. Approved the audited 2024 Financial Statements.

(Contents: As per Proposal No. 01/2025/TT-DHĐCĐ-DLVN dated 16/06/2025)

- Valid: 21,904,835 voting shares, accounting for 100% of the total votes of all shareholders attending and voting in the meeting
- Invalid: 0 voting shares, accounting for 0% of the total votes of all shareholders attending and voting in the meeting
- Approve: 21,904,705 voting shares, accounting for 99.999% of the total votes of all shareholders attending and voting in the meeting
- Disapprove: 0 voting shares, accounting for 0% of the total votes of all shareholders attending and voting in the meeting
- Abstain: 130 voting shares, accounting for 0.001% of the total votes of all shareholders attending and voting in the meeting

4. Approved the audited report on the use of owner's contributed capital, with the capital contribution from the issuance of 8,650,000 shares up to December 31, 2024.

(Contents: As per Proposal No. 01/2025/TT-DHĐCĐ-DLVN dated 16/06/2025)

- Valid: 21,904,835 voting shares, accounting for 100% of the total votes of all shareholders attending and voting in the meeting

- Invalid: 0 voting shares, accounting for 0% of the total votes of all shareholders attending and voting in the meeting
- Approve: 21,904,705 voting shares, accounting for 99.999% of the total votes of all shareholders attending and voting in the meeting
- Disapprove: 0 voting shares, accounting for 0% of the total votes of all shareholders attending and voting in the meeting
- Abstain: 130 voting shares, accounting for 0.001% of the total votes of all shareholders attending and voting in the meeting

5. Approved the 2024 profit distribution and dividend plan, and the 2025 profit distribution and dividend plan.

(Contents: As per Proposal No. 01/2025/TT-DHĐCĐ-DLVN dated 16/06/2025)

- Valid: 21,904,835 voting shares, accounting for 100% of the total votes of all shareholders attending and voting in the meeting
- Invalid: 0 voting shares, accounting for 0% of the total votes of all shareholders attending and voting in the meeting
- Approve: 21,902,705 voting shares, accounting for 99.990% of the total votes of all shareholders attending and voting in the meeting
- Disapprove: 2,000 voting shares, accounting for 0.009% of the total votes of all shareholders attending and voting in the meeting
- Abstain: 130 voting shares, accounting for 0.001% of the total votes of all shareholders attending and voting in the meeting

6. Approved the 2024 remuneration, bonuses, and salaries paid, and the 2025 remuneration plan for the Board of Directors and Supervisory Board.

(Contents: As per Proposal No. 01/2025/TT-DHĐCĐ-DLVN dated 16/06/2025)

- Valid: 21,904,835 voting shares, accounting for 100% of the total votes of all shareholders attending and voting in the meeting
- Invalid: 0 voting shares, accounting for 0% of the total votes of all shareholders attending and voting in the meeting
- Approve: 21,904,641 voting shares, accounting for 99.999% of the total votes of all shareholders attending and voting in the meeting
- Disapprove: 0 voting shares, accounting for 0% of the total votes of all shareholders attending and voting in the meeting
- Abstain: 194 voting shares, accounting for 0.001 % of the total votes of all shareholders attending and voting in the meeting

7. Approved the selection of a financial statement auditing company in 2025.

(Contents: As per Proposal No. 01/2025/TT-DHĐCĐ-DLVN dated 16/06/2025)

- Valid: 21,904,835 voting shares, accounting for 100% of the total votes of all shareholders attending and voting in the meeting
- Invalid: 0 voting shares, accounting for 0% of the total votes of all shareholders attending and voting in the meeting
- Approve: 21,904,705 voting shares, accounting for 99.999% of the total votes of all shareholders attending and voting in the meeting
- Disapprove: 0 voting shares, accounting for 0% of the total votes of all shareholders attending and voting in the meeting
- Abstain: 130 voting shares, accounting for 0.001% of the total votes of all shareholders attending and voting in the meeting

8. Approved the plan to issue shares to pay dividends to existing shareholders.

(Contents: As per Proposal No. 02/2025/TT-ĐHĐCĐ-DLVN dated 16/06/2025)

- Valid: 21,904,835 voting shares, accounting for 100% of the total votes of all shareholders attending and voting in the meeting
- Invalid: 0 voting shares, accounting for 0% of the total votes of all shareholders attending and voting in the meeting
- Approve: 21,902,705 voting shares, accounting for 99.990% of the total votes of all shareholders attending and voting in the meeting
- Disapprove: 2,000 voting shares, accounting for 0.009% of the total votes of all shareholders attending and voting in the meeting
- Abstain: 130 voting shares, accounting for 0.001% of the total votes of all shareholders attending and voting in the meeting

9. Approved the share offering plan to increase charter capital.

(Contents: As per Proposal No. 03/2025/TT-ĐHĐCĐ-DLVN dated 16/06/2025)

- Valid: 21,904,835 voting shares, accounting for 100% of the total votes of all shareholders attending and voting in the meeting
- Invalid: 0 voting shares, accounting for 0% of the total votes of all shareholders attending and voting in the meeting
- Approve: 21,904,705 voting shares, accounting for 99.999% of the total votes of all shareholders attending and voting in the meeting
- Disapprove: 0 voting shares, accounting for 0% of the total votes of all shareholders attending and voting in the meeting
- Abstain: 130 voting shares, accounting for 0.001% of the total votes of all shareholders attending and voting in the meeting

VIII. ELECTION RESULTS

Based on the Report from the Vote Counting Committee, the list of elected Supervisory Board members for the Company for the remainder of the 2021-2026 term is as follows:

No.	Full name	Elected position	Number of votes (votes)	Confidence Rate (%)
1	Mr. Nguyen Chi Hieu	Members of Supervisory Board	21,904,835	100%

IX. CLOSING PROCEDURES OF THE GENERAL MEETING

The Head of the General Meeting Secretariat read the Minutes and the draft Resolution of the General Meeting for approval.

The General Meeting of Shareholders unanimously approved the full text of the Minutes and the Resolution of the General Meeting on the spot, through a show of voting cards, with an affirmative vote reaching **21,904,835 voting shares**, accounting for **100%** of the total votes of all shareholders attending and voting in the meeting.

The 2025 Annual General Meeting of Shareholders of Viet Nam Medicinal Materials Joint Stock Company was successfully held and concluded at 11:45 A.M on the same day, June 16, 2025.

ON BEHALF OF THE
SECRETARIAT



NGUYEN HA VAN

ON BEHALF OF THE PRESIDIUM
CHAIRMAN



NGUYEN VAN CAI

RESOLUTION

ANNUAL GENERAL MEETING OF SHAREHOLDERS IN 2025

(Annual General Meeting of Shareholders on June 16, 2025)

Base:

- Enterprise Law No. 59/2020/QH14 dated June 17, 2020, and its guiding implementation documents;
- Securities Law No. 54/2019/QH14 dated November 26, 2019, and its guiding implementation documents;
- The Charter on organization and operation of Viet Nam Medicinal Materials Joint Stock Company;
- Minutes of the 2025 Annual General Meeting of Shareholders of Viet Nam Medicinal Materials Joint Stock Company No. 01/2025/BBH-ĐHĐCĐ-DLVN dated June 16, 2025;
- The legality of the General Meeting:

The General Meeting of Shareholders of Viet Nam Medicinal Materials Joint Stock Company on June 16, 2025, was held at Muong Thanh Luxury Phu Tho Hotel, Lot CC17, Hung Vuong Square, Gia Cam Ward, Viet Tri City, Phu Tho Province.

- Total number of shareholders convened: 2,155 shareholders representing 42,779,916 voting shares, accounting for 100% of the total voting shares (as per the consolidated list of securities owners finalized by Vietnam Securities Depository and Clearing Corporation on May 19, 2025).
- Total number of delegates attending the General Meeting: **37 people**, owning and representing **21,904,835 shares** equivalent to **51.2%** of the total shares.
- Based on the Minutes of the 2025 Annual General Meeting of Shareholders of Viet Nam Medicinal Materials Joint Stock Company No. 01/BBH-ĐHĐCĐ-DLVN dated June 16, 2025.
- Based on the voting results by voting cards, the vote counting minutes, and the election vote counting minutes at the 2025 Annual General Meeting of Shareholders of Viet Nam Medicinal Materials Joint Stock Company on June 16, 2023.



RESOLUTIONS:

- Article 1.** Approved the 2024 operational report of the Company's Board of Directors; the direction and operational plan of the Board of Directors for 2025.
(As per Report No. 01/2025/BC-HĐQT-DLVN dated 16/06/2025 attached).
- Article 2.** Approved the 2024 operational report of the Supervisory Board and the plan for 2025.
(As per Report No. 02/2025/BC-BKS-DLVN dated 16/06/2025 attached).
- Article 3.** Approved the audited 2024 Financial Statements.
(As per Report No. 01/2025/TT-ĐHĐCĐ-DLVN dated 16/06/2025 attached).
- Article 4.** Approved the audited report on the use of owner's contributed capital, with the capital contribution from the issuance of 8,650,000 shares up to December 31, 2024.
(As per Report No. 01/2025/TT-ĐHĐCĐ-DLVN dated 16/06/2025 attached).
- Article 5.** Approved the 2024 profit distribution and dividend plan, and the 2025 profit distribution and dividend plan.
(As per Report No. 01/2025/TT-ĐHĐCĐ-DLVN dated 16/06/2025 attached).
- Article 6.** Approved the 2024 remuneration, bonuses, and salaries paid, and the 2025 remuneration plan for the Board of Directors and Supervisory Board.
(As per Report No. 01/2025/TT-ĐHĐCĐ-DLVN dated 16/06/2025 attached).
- Article 7.** Approved the selection of the audit firm for the 2025 financial statements.
(As per Report No. 01/2025/TT-ĐHĐCĐ-DLVN dated 16/06/20255 attached).
- Article 8.** Approved the plan to issue shares to pay dividends to existing shareholders
(As per Report No. 02/2025/TT-ĐHĐCĐ-DLVN dated 16/06/20255 attached).
- Article 9.** Approved the plan for offering shares to increase charter capital.
(As per Report No. 03/2025/TT-ĐHĐCĐ-DLVN dated 16/06/2025 attached).
- Article 10.** Supplementing the Internal Corporate Governance Regulation with provisions on online meetings to ensure compliance with the current regulations.
(As per Report No. 01/2025/TT-ĐHĐCĐ-DLVN dated 16/06/2025 attached).
- Article 11.** Approving the dismissal of the Supervisory Board members who submitted their resignations as follows:

No	Full name	Position
1	Ms. Nguyen Diep Khanh Linh	Head of the Supervisory Board

(As per Report No. 04/2025/TT-ĐHĐCĐ-DLVN dated 16/06/2025 attached).

Approving the list of candidates for the position of members of the Supervisory Board for the remaining time of the 2021-2026 term:

No	Full name	Nominated Position
1	Mr. Nguyen Chi Hieu	Members of the Supervisory Board

(As per Report No. 04/2025/TT-ĐHĐCĐ-DLVN dated 16/06/2025 attached).

Approving the list of candidates elected to the positions of members of the Supervisory Board for the remaining time of the 2021-2026 term

STT	Full name	Elected position	Vote count	Percentage (%) / total votes
1	Mr. Nguyen Chi Hieu	Members of the Supervisory Board	21,904,835	100%

Article 12. Enforcement Clause:

This Resolution was approved at the 2025 Annual General Meeting of Shareholders and takes effect from June 16, 2025.

Members of the Board of Directors and the Board of Management are responsible for implementing and organizing the execution of this Resolution according to their respective functions, duties, and powers, in compliance with current laws and the Charter on organization and operation of Viet Nam Medicinal Materials Joint Stock Company.

ON BEHALF OF THE PRESIDIUM

Recipient:

- General Meeting of Shareholders (Company website);
- HOSE, SSC (Information Disclosure);
- Board of Directors, Supervisory Board;
- Board of Management;
- Save VP, TL.



NGUYEN VAN CAI